Hydrochloric Acid

Hydrochloric Acid

SCHEMBL3281364

CCCCCCCC/C=C\CCCCCCCC(=O)OCCN1CC[N+](CCO)=C1C(=O)CCCCCCC/C=C\CCCCCCCC.[Cl-]

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.45
EPHX2 P34913 1/20 0.42
DGKA P23743 2/20 0.41
PRKCA P17252 3/20 0.40
PRKCE Q02156 1/20 0.40
PRKCQ Q04759 1/20 0.40
PRKCD Q05655 1/20 0.40
FAAH O00519 1/20 0.40
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL421820 1.00 MGLL (0.45) MGLLEPHX2DGKAPRKCAPRKCE
SCHEMBL19133947 0.99 MGLL (0.46) MGLLEPHX2DGKAPRKCAPRKCE
SCHEMBL441410 0.99 MGLL (0.46) MGLLEPHX2DGKAPRKCAPRKCE
Hydrochloric Acid SCHEMBL421819 0.87 MGLL (0.46) MGLLEPHX2DGKAPRKCAPRKCE
Hydrochloric Acid SCHEMBL4074680 0.87 MGLL (0.46) MGLLEPHX2DGKAPRKCAPRKCE
Water SCHEMBL6549696 0.85 MGLL (0.46) MGLLEPHX2DGKAPRKCAPRKCE
Hydrochloric Acid SCHEMBL18209371 0.81 DGKA (0.47) MGLLEPHX2DGKAPRKCACNR2
Hydrochloric Acid SCHEMBL888280 0.81 DGKA (0.47) MGLLEPHX2DGKAPRKCACNR2
Hydrochloric Acid SCHEMBL25292894 0.80 MGLL (0.43) MGLLEPHX2DGKAPRKCAPRKCE
Hydrochloric Acid SCHEMBL6706588 0.80 MGLL (0.43) MGLLEPHX2DGKAPRKCAPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2763657-B1 MOLECULE MIXTURE COMPRISING AN AMPHIPATHIC MOLECULE TYPE A, WHICH HAS A POSITIVE TOTAL CHARGE IN THE HYDROPHILIC RANGE, AND AN AMPHIPATHIC MOLECULE TYPE B AND A POLYPHENOL C, METHOD FOR PRODUCING SAID MOLECULE MIXTURE AND USE THEREOF FORSCHUNGSZENTRUM JUELICH GMBH (DE) 2020-03-25 EP claimed
US-20250277267-A1 TECHNIQUE FOR DIAGNOSING AND MONITORING NEURODEGENERATIVE DISEASES ON BASIS OF BODY FLUID ANALYSIS KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2025-09-04 US disclosed
EP-4334333-A1 CHIMERIC IMMUNOGENS AND METHODS FOR MAKING POLYCLONAL ANTIBODIES AGAINST SPECIFIC EPITOPES Agilent Technologies, Inc. (US) 2024-03-13 EP disclosed
CN-117597109-A Single use of polymer vesicle-associated adjuvants for stimulating immune responses ACM 生物实验室私人有限公司 2024-02-23 CN disclosed
US-20240002934-A1 COMPOSITION FOR DETECTING TARGET NUCLEIC ACID AND METHOD FOR DETECTING TARGET NUCLEIC ACID USING SAME KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2024-01-04 US disclosed
CN-117222656-A Chimeric immunogens and methods for preparing polyclonal antibodies directed against specific epitopes 安捷伦科技有限公司 2023-12-12 CN disclosed
CN-112040941-A In situ method of inducing an immune response 阿托莎医疗公司 2020-12-04 CN disclosed
CN-111936152-A Method for intraductal treatment of mammary disorders 阿托莎医疗公司 2020-11-13 CN disclosed
EP-3700564-A1 IMMUNOSTIMULATORY COMPOSITIONS Bayer Animal Health GmbH (DE) 2020-09-02 EP disclosed
WO-2019115385-A1 IMMUNOSTIMULATORY COMPOSITIONS BAYER ANIMAL HEALTH GMBH (DE) 2019-06-20 WO disclosed
WO-2012132022-A9 AGENT FOR PROMOTING GENE TRANSFER AND METHOD OF GENE TRANSFER USING THE SAME FUKUOKA PREFECTURAL GOVERNMENT (JP) 2015-01-15 WO disclosed
US-20130058994-A1 LIPOSOMES CONTAINING OLIGOPEPTIDE FRAGMENTS OF MYELIN BASIC PROTEIN, A PHARMACEUTICAL COMPOSITION AND A METHOD FOR TREATMENT OF MULTIPLE SCLEROSIS LIPOXEN TECHNOLOGIES LIMITED (GB) 2013-03-07 US disclosed
WO-2012132022-A1 AGENT FOR PROMOTING GENE TRANSFER AND METHOD OF GENE TRANSFER USING THE SAME FUKUOKA PREFECTURAL GOVERNMENT (JP) 2012-10-04 WO disclosed
US-7709457-B2 treating bladder cancer; transfecting with polynucleotide into urothelial cells; improved transfection efficiency with cationic lipids, cationic polymers or dendrimers; improve drug delivery with a solubilized cholesterol GENECURE PTE LTD. (SG) 2010-05-04 US disclosed
US-20090054364-A1 treating bladder cancer; transfecting with polynucleotide into urothelial cells; improved transfection efficiency with cationic lipids, cationic polymers or dendrimers; improve drug delivery with a solubilized cholesterol GENECURE PTE LTD. 2009-02-26 US disclosed
US-7320963-B2 Transfecting polynucleotide into cells; obtain transfection mixture, incubate with solublize in cholesterol mixture, expose with cells, recover transfected cells GENECURE PTE LTD (SG) 2008-01-22 US disclosed
EP-1208218-B1 METHODS AND COMPOSITIONS FOR DELIVERY OF PHARMACEUTICAL AGENTS GENECURE PTE LTD (SG) 2005-03-30 EP disclosed
US-20020146830-A1 Transfecting polynucleotide into cells; obtain transfection mixture, incubate with solublize in cholesterol mixture, expose with cells, recover transfected cells GENECURE PTE LTD (SG) 2002-10-10 US disclosed
EP-1208218-A2 METHODS AND COMPOSITIONS FOR DELIVERY OF PHARMACEUTICAL AGENTS Genecure Pte Ltd (SG) 2002-05-29 EP disclosed
WO-2001015755-A2 METHODS AND COMPOSITIONS FOR DELIVERY OF PHARMACEUTICAL AGENTS GENECURE PTE LTD (SG) 2001-03-08 WO disclosed